ID: ALA143426

Max Phase: Preclinical

Molecular Formula: C19H26N2O2

Molecular Weight: 314.43

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCCCN1CCC(COC(=O)c2c[nH]c3ccccc23)CC1

Standard InChI:  InChI=1S/C19H26N2O2/c1-2-3-10-21-11-8-15(9-12-21)14-23-19(22)17-13-20-18-7-5-4-6-16(17)18/h4-7,13,15,20H,2-3,8-12,14H2,1H3

Standard InChI Key:  DEWPDCSLWTYBEZ-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 314.43

Molecular Weight (Monoisotopic): 314.1994

AlogP: 3.84

#Rotatable Bonds: 6

Polar Surface Area: 45.33

Molecular Species: BASE

HBA: 3

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 4

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 12.19

CX Basic pKa: 9.96

CX LogP: 3.89

CX LogD: 1.37

Aromatic Rings: 2

Heavy Atoms: 23

QED Weighted: 0.82

Np Likeness Score: -0.73

References

1. Gaster LM, Joiner GF, King FD, Wyman PA, Sutton JM, Bingham S, Ellis ES, Sanger GJ, Wardle KA..  (1995)  N-[(1-butyl-4-piperidinyl)methyl]-3,4dihydro-2H-[1,3]oxazino[3,2- a]indole10-carboxamide hydrochloride: the first potent and selective 5-HT4 receptor antagonist amide with oral activity.,  38  (24): [PMID:7490724] [10.1021/jm00024a002]

2. Gaster L, Wyman P, Ellis E, Brown A, Young T.  (1994)  5-HT4receptor antagonists : oxazolo, oxazino and oxazepino[3,2-a]indole derivatives,  4  (5): [10.1016/S0960-894X(01)80176-1]

Source

Source(1):

• Scientific Literature